Household income and LDL-C goal attainment in patients with diabetes and dyslipidemia in a Canadian dataset Abstract Purpose: ere is evidence of a social disparity pertaining to the epidemiology and burden of illness of diabetes.
Diabetes is a chronic disease with high incidence, and prevalence, and a signi cant burden of illness [1] . An estimated 285 million people worldwide are a ected by diabetes [2] . With a further 7 million people developing diabetes each year, this number is expected to reach 438 million by 2030 [2] . ere are vast social and ethnic disparities regarding the epidemiology and burden of illness of diabetes [3] . Di erences in morbidity and mortality related to diabetes are associated with socioeconomic status, ethnicity and gender, and socioeconomic status is a key factor a ecting quality of health and health disparity [4] . A large proportion of the total health inequality is due to income-related health inequality and income may be a mediator of disparity in health care [5] . e objective of this study was to assess the association of household income strata with Canadian therapeutic goal achievement rates for LDL-C (less than 2.5 mmol/L) in diabetic patients in a Canadian dataset.
Methodology e data were derived from a previous cross-sectional study [6, 7] . Patients lling a prescription for a lipid-lowering drug between September 2004 and June 2005 in selected pharmacies in Nova Scotia, uebec, Ontario and British Columbia were eligible to participate in this study. Patients were given an information sheet and a consent form. Patients who agreed to participate signed a consent form giving permission for: (1) the research team to contact them by telephone to ask questions about their lipid lower medication utilization and health; (2) the pharmacist to release the patient's medication pro le for the previous 12 months; and, (3) the family physician to release to the research team medical information related to dyslipidemia therapy and cardiovascular risk, from the patient's medical record. Patients with any of the following criteria were excluded from study: (1) unable to speak either English or French; (2) hearing impaired; (3) cognitively impaired; (4) did not have their own telephone; and, (5) non-community dwelling (i.e., institutionalized). Eligible patients were subsequently interviewed over the telephone by trained interviewers using computer-assisted interviewing so ware (CATI). Physicians who were identi ed by the participating patients as their health care provider were requested to complete a short questionnaire pertaining to information that would be in the patient's medical record. e data obtained from the patient telephone interviews, pharmacist medication dispensing histories and physician medical records included patient characteristics (age, sex, education, height, weight, income, racial background), lipid pro le (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides), duration and dose of lipid-lowering medication use, adverse events and adherence (including reasons for discontinuation of prior therapy), non-pharmacological interventions (i.e., dietary modi cations and exercise), co-morbid conditions (e.g., peripheral vascular disease, diabetes, etc), comedications, cardiovascular risk factors and quality of life . A subset of this cohort who had diabetes was selected for the present study (277 patients). A power analysis for a sample size of 277 patients, with type one error of 5% and a di erence of LDL-C goal achievement of 10% indicates a power of more than 90%. With a di erence of LDL-C goal achievement of 5% and 8%, the power would be 40% and 80%, respectively. e data used for the present study included patient characteristics and socioeconomics data (household income, age, sex, BMI), presence of CV risk factors other than diabetes and dyslipidemia (i.e., peripheral vascular disease, hypertension, previous CV events, family history of premature coronary heart disease or stroke, smoking) and lipid pro le (LDLcholesterol). In this cross-sectional study the latest LDL-C post-therapy was reported by primary healthcare providers. As the data was gathered in 2004 and 2005, the 2003 Canadian guidelines for the management of diabetes and dyslipidemia were used to assess LDL cholesterol goal achievement [8, 9] . e threshold of successful treatment for reduction of LDL-C at that time was LDL-C less than 2.5 mmol/L according to 2003 Canadian guidelines; however, the guidelines have since been changed and in 2006 the LDL-C goal for diabetes was reduced to a target of less than 2.0 mmol/L [10] [11] [12] . Of note, assessment of goal attainment for blood glucose using HgbA1c was not possible, as the data for HgbA1c was not available for almost one-third of the patients with diabetes. e cohort of patients was ranked according to household income. Seven household income strata were de ned in the cohort from less than 20,000 CDN$, up to more than 70,000 CDN$ by increments of 10,000 CDN$. Achievement of LDL-C goal for each income strata according to the Canadian guidelines was assessed and then incorporated into logistic regression models corresponding to household income strata. e analyses were adjusted for covariates including age, sex, cardiovascular risk factors or metabolic syndrome status. e data are presented as means (standard deviations) and number (percentage). All statistical analyses were performed using SPSS program version 9.0.
Results e diabetes cohort contained 277 patients. Data describing the cohort are presented in Tables 1 and 2 . Mean age was 64 years with a standard deviation of 10 years. Average (standard deviation) number of cardiovascular risk factors per patient was 3.9 (0.9). e mean BMI was 30 kg/m 2 and 77% of the Farahani & Levine. Household income and diabetes cohort met the criteria for metabolic syndrome. e rank of income strata divided the cohort into 7 levels with an increment of 10,000 CDN$ from less than 20,000 CDN$, up to more than 70,000 CDN$ (Table 1 ). e results demonstrated that there were no signi cant di erences in patient characteristics (age, sex, BMI) and cardiovascular risks according to the household income strata in this cohort. Although, the mean ages of patients in all household income strata were similar, more patients in lower income strata were older than 65 (Pvalue = 0.001). LDL-C goal was attained in 34% of patients in the total cohort. ere was no signi cant di erence amongst household income strata for LDL-C (P-value = 0.80) goal achievement. An additional analysis was conducted dichotomizing household income into less than or equal to 40,000 CDN$ and more than 40,000 CDN$ (Table 2) . With a single cut point of 40,000 CDN$, the outcomes for LDL-C goal attainment were not signi cantly di erent: 33% versus 37% (Pvalue = 0.30).
Discussion e current study demonstrates that, in this dataset, household income was not a factor for diabetic patients to achieve the therapeutic goal for LDL-C. is may re ect that in the Canadian healthcare system, in which healthcare delivery including providers' fees, hospitalization and medication costs for patients older than 65 is reimbursed by the government for all patients who seek therapeutic interventions, household income is not a determinant of LDL-C goal achievement.
Studies on the relationship between income inequality and health have been conducted using various levels of data, from the census track level to the national level based on cross sectional and time series data. e measures of health outcome also varies; including self-assessed health status, mortality rate and life expectancy. e present study is di erent from other Canadian studies regarding outcome measures, patient population and the level of approach. e present study included a small sample size and used a cross-sectional data; however, the data are derived from individual patients (particularly important for the outcome of LDL-C). Although patients were represented in all the income strata, the patients included in the study were already able to re ll their medications based on the recruitment process. e results of this study should be interpreted with the recognition that this study has several limitations including small sample size, a potential recruitment bias and a lack of data on third party insurance coverage. Using recruitment from pharmacies limits the generalizability of the results to the Canadian population able to a ord lling a prescription for a lipid lowering drug. Also, there was a higher percentage of patients in lower income strata that were older than 65 years despite a similar mean age across the income strata. In most provinces in Canada, patients older than 65 years are eligible for medication coverage through their provincial governmental. With or without adjustment for age, LDL-C goal achievement did not change in this study. Another Canadian study using a population-based administrative database found a di erence in mortality that was related to income-related di erences among people with diabetes [13] . e study reported an overall mortality decreased by more than 30% from 1994/95 to 2005/06; however, analysis by income quintile demonstrated that the improvement in mortality was signi cantly smaller among people in lower income neighbourhoods than among those in wealthier neighbourhoods. e outcome measure was all-cause mortality and, therefore, it could not conclude whether the causes of death were similar across income groups. Also, the study did not have income data at the individual level, just neighbourhood income. e paradox of the results for that study and our present study could indicate the important di erences between individual level data for a patient versus administrative databases for the population, as well as di erences between crosssectional studies using surrogate endpoints versus longitudinal cohort studies using hard endpoints.
In another Canadian cross-sectional study, low income patients presenting to a diabetes clinic were older, heavier and had a more atherogenic lipid pro le than high income patients [14] . Overall medication use was higher among the lower income group, suggesting that di erences in clinical pro les were not the result of under-treatment, thus invoking lifestyle factors as potential contributors to these ndings [14] . In our study, the patients' characteristics (age and BMI) as well as cardiovascular risks were distributed similarly by household income strata, which could re ect more homogeneity in this patient population compared to the study by Rabi et al. In another study, the same group of researchers used data from a regional Diabetes Education Centre (DEC), the Canadian National Diabetes Surveillance System (NDSS) and the 2001 Canadian Census [15] . eir analysis illustrated that low income was associated with a higher prevalence of diabetes and a higher population rate of referral to the regional DEC; however, a er accounting for diabetes prevalence, the equal proportions referred to the DEC across all the income groups suggested that there was no access bias based on income [15] . is could indicate that in the Canadian publicly-funded system, access to healthcare providers including doctors, diabetes educators and diabetes nurses is independent of income.
In contrast, a random-digit dialling study on patients with diabetes in Ontario demonstrated low socioeconomic status (as characterized by annual household income <$30,000) and absence of supplemental health insurance as key barriers to accessing and using diabetes care [16] . In this study, younger age was an independent predictor of non-adherence with diabetes medication, glucose testing and the purchase of healthy foods due to cost.
In a population-based retrospective cohort study using administrative health claims from Ontario, employing a composite outcome of death, nonfatal acute myocardial infarction (AMI) and nonfatal stroke in adults with diabetes, the results demonstrated that socioeconomic di erences in CVD burden diminished substantially a er age 65 years [17] . e study suggested that the results were a re ection of the di erence between the comprehensive access to medications and diabetes testing products for patients aged more than 65 years in Ontario compared with the variable coverage for persons less than 65 years. In our study, the mean age was close to 65 years and many patients in this cohort were from Ontario. As aforementioned, a higher percentage of patients in the lower income strata were older than 65 years despite a similar mean age across the strata; however, LDL-C goal achievement did not change with or without adjustment for age.
A study using the aggregate data from the Public Use Microdata Files (PUMF) of Canadian National Population Health Survey to estimate income-related health inequalities across the ten Canadian provinces concluded that health inequalities favoring the higher income people do exist in all provinces when health status is either self-assessed or measured by the health utility index [18] . e outcome measure for LDL-C was not included in the population health survey.
Wilkinson and Pickett in 2006 compiled the results from 155 published peer-reviewed papers on the relationship between income inequality and population health [19] . Approximately 70% of the results suggested that health status was lower in societies where income was more unequal. Wagsta and van Doorslaer also reported that approximately 25% of the total health inequality was due to income-related or socioeconomic inequality amongst Canadian adults [20] . Furthermore, van Doorslaer and Jones found that around 30-40% of health inequalities in Canada could be contributed to income-related health inequality [21] .
On the other hand, Subramanian and Kawachi in 2004 reviewed the literature that investigated the empirical relationship between income inequality and health [22] . ey found that the evidence implicating income disparities as a determinant factor for population health inequality was far from complete. ey argued that better data and more sophisticated analytical methods are essential for connecting income inequality to public health [22] . Wagsta and van Doorslaer in 2000 reFarahani & Levine. Household income and diabetes viewed the literature on the negative e ects of income inequality on population health [23] . Various hypotheses were identi ed that explained the observed association between measures of income inequality and population health. ey concluded that data from aggregate-level studies of the e ect of income inequality on health, i.e. studies at the population and community levels, were largely insu cient to discriminate between competing hypotheses.
ey also found that only individual-level studies had the potential to discriminate between most of the advanced hypotheses. Overall, the absoluteincome hypothesis was the most likely to explain the frequently observed strong association between population health and income inequality levels [23] . Deaton and Lubotsky found that a er controlling for the racial composition of a population in a city, the e ect of income inequality on health disappeared [24] . Cross-section regressions across American states and cities showed that, conditional on racial composition, income inequality did not raise the risk of mortality. Gravelle and colleagues examined the validity of income-related inequality and health status using aggregate data [25] . e purported relationship between income inequality and population health was not signi cant in any of their models. ey also contended that there were serious conceptual di culties in using aggregate cross-sections as a means of testing hypotheses about the e ect of income, and its distribution, on the health of individuals.
In conclusion, this study demonstrates that household income was not a factor to achieve therapeutic goals for LDL-C for patients with diabetes in this dataset, although goal attainment was less than ideal overall. It would, however, be desirable to develop large databases that capture clinical outcomes at a patient level for future research studies on the impact of income on health/disease status, instead of relying on large administrative population-based databases that utilize a cluster of information from the population level to tease out the outcomes in the patients' individual level.
